Second-Line Ramucirumab, Avelumab, and Paclitaxel in Esophagogastric Adenocarcinoma

Peter Thuss-Patience,Anica Högner,Eray Goekkurt,Michael Stahl,Albrecht Kretzschmar,Thorsten Götze,Gertraud Stocker,Peter Reichardt,Frank Kullmann,Daniel Pink,Prisca Bartels,Armin Jarosch,Axel Hinke,Christoph Schultheiß,Lisa Paschold,Alexander Stein,Mascha Binder
DOI: https://doi.org/10.1001/jamanetworkopen.2023.52830
2024-01-24
JAMA Network Open
Abstract:This nonrandomized controlled trial investigates efficacy and tolerability of the combination of avelumab with paclitaxel plus ramucirumab in the treatment of metastatic esophagogastric adenocarcinoma.
medicine, general & internal
What problem does this paper attempt to address?